ALK and non-small cell lung carcinoma: One thing to be noticed was that the PFS results in our study was longer than the newest result from PROFILE‐1029, a phase III randomized controlled trial which compared crizotinib with chemotherapy in the first‐line treatment of east Asian ALK‐positive NSCLC patients 33.